The end of 'leaky gut': pathway-specific mechanistic approaches to barrier restoration [0.03%]
“肠道渗漏”终结论：屏障修复的途径特异性机制方法
Ziru Sha,Asha Bhardwaj,Jerrold R Turner
Ziru Sha
Purpose of review: For over 50 years, increased intestinal permeability has been associated with diverse inflammatory and systemic diseases. Yet the oversimplified concept of 'leaky gut' as a singular phenomenon has limit...
The Dallas Consensus for performing and interpreting functional lumen imaging probe panometry: what it means for the clinician [0.03%]
功能性腔内影像探头肠镜的临床实践与解读：达拉斯共识
Anh D Nguyen
Anh D Nguyen
Purpose of review: Functional lumen imaging probe (FLIP) panometry is being increasingly used to evaluate esophageal motility at the time of endoscopy. This review explains how the recently published Dallas Consensus prov...
Reena Sidhu
Reena Sidhu
Vitchapong Prasitsumrit,Vincent L Chen
Vitchapong Prasitsumrit
Purpose of review: Discuss advances in genomics, metabolomics, and proteomics in steatotic liver disease. Recent findings: Common genet...
The utility of albumin in cirrhosis: established benefits and unanswered questions [0.03%]
白蛋白在肝硬化治疗中的作用：已证实的益处和悬而未决的问题
Karim Besir,Don C Rockey
Karim Besir
Purpose of review: Albumin plays a central role in maintaining circulatory and endothelial homeostasis through its oncotic and nononcotic effects. In cirrhosis, reduced concentration and impaired function of albumin contr...
The use of potassium-competitive acid blockers in the management of foregut disease [0.03%]
钾竞争性酸阻滞剂在前肠疾病治疗中的应用
Megan B Ghai,Joshua A Sloan
Megan B Ghai
Purpose of review: The purpose of this review is to explore the current clinical evidence evaluating the use of potassium-competitive acid blockers (PCABs) in the management of foregut diseases. ...
Nonyelum Ebigbo
Nonyelum Ebigbo
Purpose of review: Interest in the esophageal microbiome has expanded rapidly, yet its functional and clinical relevance remains incompletely defined. This review synthesizes emerging evidence on host-microbe interactions...
Glucagon-like peptide agonists and use in short bowel syndrome - what about the side effects? [0.03%]
胰高血糖素样肽受体激动剂在短肠综合征中的应用及其副作用问题？
Lucy Gorard,Megan Boucher,Charlotte Rutter
Lucy Gorard
Purpose of review: This review summarizes recent evidence on the use of glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) agonists in the management of short bowel syndrome (SBS), with a focus on emergin...
Manisha Verma,Hamza Tahir,Richard Kalman
Manisha Verma
Purpose of review: Despite significant progress in evidence-based therapies and models of care, hepatology continues to face challenges in translating proven interventions into routine clinical practice. Variability in ad...
Are we missing early pancreatic dysfunction? Expanding faecal elastase testing beyond pancreatic disease [0.03%]
我们忽视了早期胰腺功能不全吗？粪便弹性蛋白酶检测的临床应用超出了胰腺疾病
Connor E M Cotton,Andrew D Hopper,David S Sanders
Connor E M Cotton
Purpose of review: Pancreatic exocrine insufficiency (PEI) has long been associated with intrinsic pancreatic disease, yet emerging evidence shows it is under-recognized in patients with nonspecific gastrointestinal sympt...